Tempus, the cancer technology company co-founded by Eric Lefkofsky, received a large infusion of funds to aid people undergoing treatment for the disease. In the company’s latest round of fundraising, new and existing investors contributed $80 million to the company. This now puts Tempus’s assets at more than $1 billion. Some of the firms that have invested in Tempus include T. Rowe Price and New Enterprise Associates. Since Lefkofsky co-founded Tempus in 2015, the company has built a database of clinical and molecular data on nearly 20,000 cancer patients. This provides streamlined information for physicians to help them develop more personalized care for their patients.
This allows Tempus to provide genomic sequencing services and therapeutic data so physicians can make data driven decisions on how best to treat their patients. While Tempus specializes in medical data, Eric Lefkofsky himself did not have a medical background prior to forming the company. Some of his previous endeavors include founding the Lightbank, which invests in disruptive technologies, Echo Global Logistics, a technology-enabled transportation and logistics outsourcing firm, and he invested in Uptake Technologies, a predictive analytics platform for the world’s largest industries.
A graduate of the University of Michigan, Lefkofsky has also established the Lefkofsky Foundation to support scientific and educational organizations around the world. Lefkofsky said the $80 million in new funding will help Tempus’s efforts as it continues to grow. He explained the company is adding on average 30 new employees a month as it seeks to expand its data base of patients to aid physicians in their treatment. Lefkofsky added that to help unlock the mysteries of cancer, a lot of data is needed, and Tempus will help compile that information.
Human Genome Sequencing is a topic that has long since been on the radar in many fields of medicine. By performing human genome sequencing, molecular data about an individual can be collected. It is believed that that data holds “secrets” about us as humans and when faced with a disease, ailment or cancer, that data can also hold secrets about the disease. By collecting this data, we are able to see a better picture of how humans are affected by and react to different diseases and learn more about Eric.
Tempus is a company that was founded in 2016 by entrepreneur Eric Lefkofsky that is attempting to push forward with human genome sequencing to collect molecular data on patients affected with cancer. That data would be paired with data collected from physicians notes and progress data into a massive digital library that would be easily accessible to physicians working with cancer patients. The end goal of Tempus is a lofty one, but attainable based upon the strides made in just one short year. Tempus wants to build the world’s largest library of collected molecular and clinical data and sync it into a seamless operating platform to make the combined data accessible and useful to treating cancer.
Human genome sequencing has not been as widely used in past years as it probably should have been. Several years ago, it typically cost close to $100 million dollars. Today, that cost has dropped to around $5,000. With technology companies like Tempus pushing forward to make advancements through human genome sequencing, it is hopeful that the cost will be lowered even more in the near future and more information click here.
Tempus co-founder and President Eric Lefkofsky is a well-known technology innovator. He is famous as a technology disruptor and has had multiple successful endeavors in the technology industry throughout several decades. He is best known for co-founding Groupon and Echo Global Logistics.
He is on the board of directors for the Art Institute of Chicago, a board member of World Business Chicago and co-chairman of the Technology Council. He currently lives in Chicago with his wife. He has two daughters and two grandchildren and Eric’s lacrosse camp.
Eric Lefkofsky is famous the nation over as one of the key figures behind the highly innovative volume-discount giant Groupon. But he also became known for his magnanimity giving to cancer research. Over the course of the last decade, Lefkofsky has been one of the most prominent and lucrative donors to the cancer research establishment, with tens of millions of dollars having been given away in most years.
But when Lefkofksy’s own wife was diagnosed with advanced breast cancer, the reality of that horrible disease hit closer to home.Lefkofksy often accompanied his wife to her appointments with physicians and oncologists. As difficult as it was to deal with a loved one who had just received a cancer diagnosis, Lefkofsky became even more distraught when he realized that many of the oncologists who were charged with treating his wife’s potentially deadly condition had less access to good data than most of the nation’s truck drivers. This Lefkofsky experience made his realize there was vast room for improvement in the ways that oncologists can access and are presented with data.
He began researching the problem on his own time. He realized that, with the advent of modern, cheap genome sequencing, there is a vast trove of untapped data that can be potentially used to customize treatment regimens for cancer patients. Shortly thereafter, he founded Tempus, a company dedicated to creating systems for the collection, distribution and analysis of oncological and genomic data.
Eric Lefkofsky believes that the current model of treating cancer patients will soon be rendered obsolete by the ability of oncologists to formulate patient-tailored treatment regimens. Eric Lefkosfky states that, within just ten years, the average human genome will be able to be sequenced for just a few hundred dollars. This will create a vast reserve of powerful data that can be used to maximize individual patient outcomes.
Lefkofksy notes that today, most patients with any given type of cancer receive essentially the same treatment as all other patients suffering from that same form. With custom treatment regimens, oncologists will be able to take into account the genetic makeup of their patients, comorbidities and a whole host of other factors to design precisely the right regimen.